Kim L Isaacs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5474767/publications.pdf

Version: 2024-02-01

159585 106344 4,726 72 30 65 citations h-index g-index papers 78 78 78 4722 citing authors docs citations times ranked all docs

#	Article	IF	Citations
1	Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch. Clinical Gastroenterology and Hepatology, 2023, 21, 1663-1666.e3.	4.4	3
2	Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 28-37.	8.1	37
3	Single-Cell Analysis Reveals Unexpected Cellular Changes and Transposon Expression Signatures in the Colonic Epithelium of Treatment-NaÃ⁻ve Adult Crohn's Disease Patients. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1717-1740.	4.5	12
4	Whole-genome sequencing of African Americans implicates differential genetic architecture in inflammatory bowel disease. American Journal of Human Genetics, 2021, 108, 431-445.	6.2	21
5	Increased colonic expression of ACE2 associates with poor prognosis in Crohn's disease. Scientific Reports, 2021, 11, 13533.	3.3	14
6	Spotlight: Management of Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2020, 158, 1464.	1.3	8
7	Decreased Colonic Activin Receptor-Like Kinase 1 Disrupts Epithelial Barrier Integrity in Patients With Crohn's Disease. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 779-796.	4.5	12
8	AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology, 2020, 158, 1450-1461.	1.3	355
9	Chronic Antibiotic Dependent Pouchitis Is Associated With Older Age at the Time of Ileal Pouch Anal Anastomosis (J-pouch) Surgery. Crohn's & Colitis 360, 2019, 1, otz029.	1.1	4
10	Combined Endoscopic and Oral Fecal Microbiota Transplantation in Patients with Antibiotic-Dependent Pouchitis: Low Clinical Efficacy due to Low Donor Microbial Engraftment. Inflammatory Intestinal Diseases, 2019, 4, 1-6.	1.9	48
11	Response to Ribaldone. American Journal of Gastroenterology, 2019, 114, 826-827.	0.4	0
12	Response to Chapman and Jones. American Journal of Gastroenterology, 2019, 114, 828-828.	0.4	0
13	Preventive Health Care Among Postpartum Women With Inflammatory Bowel Disease: Results From the PIANO Registry. Inflammatory Bowel Diseases, 2019, 25, 797-802.	1.9	11
14	Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. Inflammatory Bowel Diseases, 2019, 25, 767-774.	1.9	60
15	Response to Chamberlin and Borody. American Journal of Gastroenterology, 2019, 114, 171-174.	0.4	O
16	Clinical disease activity in the CALM study. Lancet, The, 2018, 391, 1481-1482.	13.7	2
17	ACG Clinical Guideline: Management of Crohn's Disease in Adults. American Journal of Gastroenterology, 2018, 113, 481-517.	0.4	851
18	IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?. Inflammatory Bowel Diseases, 2018, 24, 698-713.	1.9	0

#	Article	IF	Citations
19	Bariatric Surgery Is a Safe and Effective Option for Patients with Inflammatory Bowel Diseases: A Case Series and Systematic Review of the Literature. Inflammatory Intestinal Diseases, 2018, 3, 173-179.	1.9	24
20	Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology, 2018, 155, 1098-1108.e9.	1.3	67
21	IBD LIVE Seriesâ€"Case 8. Inflammatory Bowel Diseases, 2017, 23, 1667-1677.	1.9	4
22	Investigator-Initiated IBD Trials in the United States. Inflammatory Bowel Diseases, 2017, 23, 14-22.	1.9	22
23	Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology, 2017, 152, 206-217.e2.	1.3	120
24	Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2016, 22, 224-233.	1.9	90
25	Use of Biologics in Pouchitis. Journal of Clinical Gastroenterology, 2015, 49, 647-654.	2.2	59
26	MicroRNAs Classify Different Disease Behavior Phenotypes of Crohn's Disease and May Have Prognostic Utility. Inflammatory Bowel Diseases, 2015, 21, 2178-2187.	1.9	68
27	Navigating the Affordable Care Act and the Patient with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2969-2974.	1.9	0
28	Accuracy of Capsule Colonoscopy in Detecting Colorectal Polyps in a Screening Population. Gastroenterology, 2015, 148, 948-957.e2.	1.3	160
29	Characterization of Genetic Loci That Affect Susceptibility to Inflammatory Bowel Diseases in African Americans. Gastroenterology, 2015, 149, 1575-1586.	1.3	65
30	Infliximab Re-treatment in Inflammatory Bowel Disease: A Single-Center Routine Clinical Experience. Clinical Gastroenterology and Hepatology, 2015, 13, 1704-1705.	4.4	0
31	If Your Physician Cannot Help, Try Cannabis: How Trial Design May Lead to Hazardous Conclusions. Clinical Gastroenterology and Hepatology, 2014, 12, 897-898.	4.4	1
32	Pregnancy Concerns in Patients with Ileal Pouch Anal Anastomosis for Ulcerative Colitis: Time for Increased Education Across Specialties. Digestive Diseases and Sciences, 2014, 59, 1075-1077.	2.3	1
33	Pregnancy and Fertility in Ulcerative Colitis. , 2014, , 273-280.		0
34	Response to letter to the Editor – Implementation of integrative approaches to improve the design of Crohn's disease clinical trials. Clinical Nutrition, 2013, 32, 148-149.	5.0	1
35	Ciprofloxacin for the Prevention of Postoperative Recurrence in Patients with Crohn $\hat{E}\frac{1}{4}$ s Disease. Inflammatory Bowel Diseases, 2013, 19, 1073-1079.	1.9	45
36	Rifaximin in IBD. Inflammatory Bowel Diseases, 2013, 19, 457-458.	1.9	O

#	Article	IF	Citations
37	Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. Clinical Nutrition, 2012, 31, 721-727.	5.0	86
38	Methotrexate: Underused and Ignored?. Digestive Diseases, 2012, 30, 112-118.	1.9	17
39	Contribution of higher risk genes and European admixture to Crohn $\hat{E}^{1}\!\!/\!\!4$ s disease in African Americans. Inflammatory Bowel Diseases, 2012, 18, 2277-2287.	1.9	29
40	Preemptive Pharmacogenetic Testing: Insufficient Data Equal Unsatisfactory Guidance. Annals of Internal Medicine, 2011, 154, 842.	3.9	9
41	Impact of capsule endoscopy on management of inflammatory bowel disease: A single tertiary care center experience. Inflammatory Bowel Diseases, 2011, 17, 1855-1862.	1.9	73
42	Efficacy of methotrexate in ulcerative colitis. Inflammatory Bowel Diseases, 2010, 16, 1421-1430.	1.9	29
43	NOD2 Mutations and Anti- Saccharomyces cerevisiae Antibodies Are Risk Factors for Crohn's Disease in African Americans. American Journal of Gastroenterology, 2010, 105, 378-386.	0.4	30
44	A randomized, controlled, double-blind trial of air insufflation versus carbon dioxide insufflation during ERCP. Gastrointestinal Endoscopy, 2010, 72, 68-77.	1.0	39
45	How Rapidly Should Remission Be Achieved?. Digestive Diseases, 2010, 28, 548-555.	1.9	24
46	Migraine in Patients With Inflammatory Bowel Disorders. Journal of Clinical Gastroenterology, 2009, 43, 499.	2.2	23
47	Role of probiotic therapy in IBD. Inflammatory Bowel Diseases, 2008, 14, 1597-1605.	1.9	92
48	How prevalent are extraintestinal manifestations at the initial diagnosis of IBD?. Inflammatory Bowel Diseases, 2008, 14, S198-S199.	1.9	13
49	Early combined immunosuppression in Crohn's disease. Lancet, The, 2008, 371, 1995-1996.	13.7	2
50	A Randomized, Placebo-Controlled, Phase II Study of Tetomilast in Active Ulcerative Colitis. Gastroenterology, 2007, 132, 76-86.	1.3	50
51	Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study. Inflammatory Bowel Diseases, 2007, 13, 1250-1255.	1.9	106
52	Crohn's disease of the esophagus. Current Treatment Options in Gastroenterology, 2007, 10, 61-70.	0.8	12
53	Design Issues and Outcomes in Ibd Clinical Trials. Inflammatory Bowel Diseases, 2005, 11, S22-S28.	1.9	37
54	Ethical Issues, Safety, and Data Integrity in Clinical Trials. Inflammatory Bowel Diseases, 2005, 11, S17-S21.	1.9	2

#	Article	IF	Citations
55	State of the Art: Ibd Therapy and Clinical Trials in Ibd. Inflammatory Bowel Diseases, 2005, 11, S3-S12.	1.9	77
56	Treatment of inflammatory bowel disease with antibiotics. Gastroenterology Clinics of North America, 2004, 33, 335-345.	2.2	48
57	Tacrolimus for the treatment of fistulas in patients with crohn's disease: a randomized, placebo-controlled trial. Gastroenterology, 2003, 125, 380-388.	1.3	364
58	Upper gastrointestinal tract endoscopy in inflammatory bowel disease. Gastrointestinal Endoscopy Clinics of North America, 2002, 12, 451-462.	1.4	28
59	Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology, 2000, 119, 1461-1472.	1.3	442
60	Hyoscyamine As A Pharmacological Adjunct in Colonoscopy: A Randomized, Double Blinded, Placebo-Controlled Trial. American Journal of Gastroenterology, 1999, 94, 2905-2908.	0.4	15
61	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology, 1999, 117, 527-535.	1.3	236
62	Severe Bone Pain as an Adverse Effect of Cyclosporin Therapy for Crohn $\hat{E}^{1}\!\!/\!\!4$ s Disease. Inflammatory Bowel Diseases, 1998, 4, 95-97.	1.9	7
63	Severe bone pain as an adverse effect of cyclosporin therapy for Crohn's disease. Inflammatory Bowel Diseases, 1998, 4, 95-97.	1.9	9
64	The use of percutaneous endoscopic gastrostomy in pregnancy. Gastrointestinal Endoscopy, 1997, 46, 564-565.	1.0	23
65	Pneumatosis intestinalis. Digestive Diseases and Sciences, 1996, 41, 2272-2285.	2.3	99
66	Crohn??s Disease. Journal of Clinical Gastroenterology, 1995, 21, 249-253.	2.2	97
67	Severe Gastrointestinal Bleeding. Clinics in Geriatric Medicine, 1994, 10, 1-17.	2.6	8
68	Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology, 1992, 103, 1587-1595.	1.3	325
69	Regulation of Macrophage Infiltration and Activation in Sites of Chronic Inflammation. Annals of the New York Academy of Sciences, 1992, 664, 93-102.	3.8	10
70	Special Diagnostic and Therapeutic Considerations in Elderly Patients with Upper Gastrointestinal Disease. Journal of Clinical Gastroenterology, 1991, 13, S65.	2.2	16
71	Pancreatitis After Rectal Administration of 5-Aminosalicylic Acid. Journal of Clinical Gastroenterology, 1990, 12, 198-199.	2.2	44
72	Esophageal Obstruction with a Dietary Fiber Product Designed for Weight Reduction. Journal of Clinical Gastroenterology, 1990, 12, 667-669.	2.2	15